Lung Cancer Genomic Testing Market by Technology (Fluorescence In Situ Hybridization, Microarray, Next Generation Sequencing), Test Type (Liquid Biopsy, Tissue Biopsy), Application, End User - Global Forecast 2025-2032
Description
The Lung Cancer Genomic Testing Market was valued at USD 1.07 billion in 2024 and is projected to grow to USD 1.16 billion in 2025, with a CAGR of 8.56%, reaching USD 2.07 billion by 2032.
A dynamic introduction framing lung cancer genomic testing as a clinical innovation transforming diagnostics and enabling personalized therapeutic decisions
Lung cancer genomic testing has evolved from a promising scientific concept into a cornerstone of contemporary oncology practice, reshaping how clinicians identify therapeutic targets and stratify patients for precision treatments. Advances in molecular biology and sequencing technologies have catalyzed a shift in diagnostic paradigms, enabling detection of actionable alterations with a level of specificity that informs both targeted therapy selection and enrollment in clinical trials. As patient pathways increasingly center on molecular characterization, the role of genomic assays extends beyond isolated diagnostics to an integrated element of care planning and longitudinal disease management.
Clinicians and laboratory leaders now confront a landscape where test choice, turnaround time, and analytic sensitivity directly influence treatment trajectories. Meanwhile, researchers leverage richer genomic datasets to refine biomarker definitions and to explore resistance mechanisms. This introduction distills those converging forces, clarifies the clinical rationale for genomic interrogation in lung oncology, and sets the stage for deeper discussion of technological, regulatory, and market dynamics that will determine adoption and implementation strategies across institutional settings.
An incisive synthesis of transformative shifts reshaping lung cancer genomics across technological advances, regulatory change, and clinician-driven adoption trends
The lung cancer genomic testing landscape is undergoing transformative shifts driven by a convergence of technological innovation, regulatory adaptation, and changing clinical workflows. Next-generation sequencing platforms have matured in throughput and analytic robustness, prompting laboratories to reconsider single-gene approaches in favor of multiplexed panels that can detect broader mutational spectra. Concurrently, improvements in sample processing and bioinformatics have reduced false negatives and enabled detection of low-frequency variants, which elevates confidence in clinical decision-making. Regulatory agencies have also moved toward clearer validation pathways and guidance for companion diagnostics, which has reduced ambiguity for developers and accelerated clinical deployment.
Adoption drivers extend beyond raw technical performance; clinician familiarity, payer engagement, and the emergence of liquid biopsy as a minimally invasive alternative have reshaped ordering behavior. At the same time, consolidation among diagnostic providers and strategic partnerships between academic centers and industry stakeholders are influencing pathways to scale. These systemic changes create both opportunities and operational challenges, requiring care providers and developers to align technology selection, quality management, and clinical utility evidence in order to optimize patient outcomes and institutional value realization.
A focused review of cumulative implications from United States tariff actions in 2025 on lung cancer genomic testing supply chains, costs and sourcing
Tariff measures introduced by the United States in 2025 have the potential to influence components of the lung cancer genomic testing ecosystem, particularly where key instruments, reagents, or specialty consumables rely on cross-border supply chains. When import duties affect sequencing platforms or essential reagents, laboratories and manufacturers may encounter higher landed costs and tighter procurement timelines, prompting reassessment of sourcing strategies. In response, some organizations may accelerate qualification of alternative suppliers, increase inventory buffers, or pursue regional procurement partnerships to mitigate exposure.
Beyond direct cost implications, tariff actions can catalyze strategic shifts in manufacturing and distribution. Domestic manufacturing investments or regionalization of supply chains may gain traction as stakeholders seek resilience against trade policy volatility. At the same time, clinical programs and diagnostic labs may prioritize assays and workflows that reduce dependency on high-cost imported consumables. Overall, while tariffs introduce complexity, they also reinforce the importance of supply chain transparency, scenario planning, and flexible contracting to sustain uninterrupted diagnostic capacity and protect patient care pathways.
A granular segmentation insight outlining technology platforms, test modalities, clinical applications, and end-user settings to guide adoption and research
A nuanced view of segment-level dynamics illuminates where clinical value and operational trade-offs converge across technology, test type, application, and end-user domains. From a technology perspective, traditional platforms such as Fluorescence In Situ Hybridization and Microarray retain roles where specific structural or copy-number assessments are required, and Real Time Polymerase Chain Reaction continues to offer rapid targeted interrogation. Sanger Sequencing remains relevant for orthogonal confirmation. At the same time, Next Generation Sequencing has become central to comprehensive genomic profiling, with targeted sequencing prioritized for focused, clinically actionable panels while whole exome and whole genome sequencing support broader discovery and complex variant interpretation in research and advanced clinical cases.
Test modality distinctions shape pre-analytical and logistical decisions. Liquid biopsy workflows that analyze circulating tumor cells and circulating tumor DNA enable minimally invasive serial monitoring and have gained traction where tissue access is limited, whereas tissue biopsy approaches such as fine needle aspiration and tissue section analyses still provide critical histopathologic and microenvironment context. Clinical applications vary by evidence need: companion diagnostics directly inform therapy selection, predictive testing anticipates therapeutic response, prognostic testing informs outcome expectations, and treatment monitoring tracks disease dynamics over time. End users span academic and research institutes focusing on discovery and validation, hospitals and diagnostic laboratories managing routine clinical testing and patient care integration, and pharmaceutical and biotechnology companies driving assay development and companion diagnostic strategies. These segmentation perspectives collectively guide investment, validation priorities, and adoption pathways for stakeholders aiming to align technology capabilities with clinical utility and operational capacity.
Regional insights revealing key drivers and barriers across the Americas, Europe Middle East & Africa, and Asia-Pacific with implications for clinical adoption
Regional dynamics exert measurable influence on how lung cancer genomic testing is deployed, reimbursed, and integrated into clinical practice. In the Americas, mature clinical infrastructures and high uptake of targeted therapies have driven demand for comprehensive genomic profiling and rapid-turnaround diagnostics. This environment encourages innovation in laboratory workflows and commercial partnerships, while regulatory clarity and payer engagement shape value demonstrations needed for broader access. In contrast, the Europe, Middle East & Africa region presents heterogeneous regulatory regimes and infrastructure maturity, requiring adaptable implementation frameworks and localized evidence generation to support clinical adoption across diverse healthcare systems.
Asia-Pacific features a mix of advanced genomic capabilities in select centers and rapidly expanding molecular diagnostics capacity in emerging markets. Regional manufacturers and public health initiatives play influential roles in scaling access, and localized validation efforts often accelerate clinical acceptance. Across regions, stakeholders must account for differences in reimbursement models, laboratory accreditation standards, and clinician education needs. Consequently, successful regional strategies blend global best practices with tailored operational models that reflect local regulatory expectations, procurement mechanisms, and patient care pathways.
An authoritative analysis of industry players highlighting strategic partnerships, technology portfolios, and competitive positioning shaping the genomic ecosystem
Industry participants are shaping the genomic testing environment through differentiated strategies that emphasize platform specialization, portfolio breadth, and collaborative development. Some organizations prioritize deep investments in bioinformatics and end-to-end laboratory automation to deliver faster, higher-fidelity results at scale, while others focus on niche assays or proprietary biomarkers to support therapeutic pipelines. Partnerships between diagnostic providers and pharmaceutical organizations have emerged as an important route to validate companion diagnostics and to streamline co-development pathways that align assay performance with therapeutic labeling and trial enrollment criteria.
Competitive positioning is also influenced by service models and quality assurance capabilities. Reference laboratories offering centralized testing can leverage scale and standardized processes, whereas academic and hospital laboratories often emphasize integrated clinical interpretation and bespoke testing tailored to complex cases. Across the ecosystem, leaders differentiate by investing in clinical evidence generation, expanding interoperability with electronic health records, and demonstrating workflow efficiencies that reduce barriers to clinician adoption. Strategic collaborations, targeted acquisitions, and co-development agreements remain central tools through which companies seek to enhance technical capability and clinical reach within the genomic ecosystem.
Practical and prioritized recommendations for industry leaders to accelerate clinical integration, optimize operational resilience, and align commercial strategies
Leaders across industry, clinical laboratories, and research institutions can advance adoption and impact by focusing on pragmatic, prioritized actions that address immediate operational constraints while positioning organizations for future technical evolution. First, aligning assay selection with clinical pathways and the institution’s therapeutic landscape reduces unnecessary complexity and accelerates clinician uptake. Second, investing in robust pre-analytical workflows and quality management mitigates variability and preserves diagnostic accuracy during scale-up. These operational investments often yield faster, more consistent results that improve clinician confidence and patient outcomes.
In parallel, stakeholders should accelerate evidence generation for clinical utility by embedding genomic testing into care pathways and prospective data collection, thereby strengthening reimbursement narratives. Strategic supplier diversification and validation of alternative reagents or platforms enhance supply chain resilience. Finally, fostering multidisciplinary education for clinicians, pathologists, and laboratory staff improves test ordering appropriateness and interpretation. Executed in combination, these recommendations support sustainable adoption, reduce time-to-result, and create clear value propositions for payers, clinicians, and patients.
A transparent research methodology describing data sources, analytical frameworks, expert validation, and the triangulation approach used to ensure rigor
The research underpinning this report combines primary expert interviews, secondary literature review, and systematic technology assessment to produce a transparent and reproducible analytic framework. Primary inputs included discussions with laboratory directors, clinical oncologists, industry strategists, and regulatory experts to surface operational realities and adoption drivers. Secondary sources provided background on technology capabilities, assay validation approaches, and regulatory guidance, and were selected to complement and corroborate primary insights rather than to serve as sole evidence.
Analytic rigor was achieved through triangulation across data sources, cross-validation of technology performance claims, and structured evaluation of clinical utility arguments. Where differences in perspective emerged, iterative expert review sessions clarified interpretation and aligned findings with practical workflows. The methodology emphasizes traceability and clarity in how conclusions were derived, enabling readers to assess evidence strength and to apply insights appropriately within their own institutional contexts.
A concise conclusion summarizing implications of genomic testing advances, policy shifts, and priorities for clinical, research and commercial stakeholders
The cumulative assessment reinforces that lung cancer genomic testing occupies a central role in contemporary oncology, with technology maturity and clinical demand accelerating integration into diagnostic pathways. Advances in sequencing and minimally invasive testing expand opportunities for earlier detection of actionable alterations and for monitoring disease evolution, but successful implementation requires coordinated attention to assay selection, quality assurance, clinician education, and supply chain robustness. Policy dynamics and regional differences further shape what operational models succeed in specific healthcare contexts.
Looking forward, stakeholders that combine thoughtful technology choices with rigorous evidence generation and resilient operational practices will be best positioned to translate genomic insights into improved patient outcomes. Collaboration across clinical, laboratory, and commercial domains will remain essential to align incentives and to ensure that diagnostic innovation meaningfully supports treatment personalization and health system value creation.
Note: PDF & Excel + Online Access - 1 Year
A dynamic introduction framing lung cancer genomic testing as a clinical innovation transforming diagnostics and enabling personalized therapeutic decisions
Lung cancer genomic testing has evolved from a promising scientific concept into a cornerstone of contemporary oncology practice, reshaping how clinicians identify therapeutic targets and stratify patients for precision treatments. Advances in molecular biology and sequencing technologies have catalyzed a shift in diagnostic paradigms, enabling detection of actionable alterations with a level of specificity that informs both targeted therapy selection and enrollment in clinical trials. As patient pathways increasingly center on molecular characterization, the role of genomic assays extends beyond isolated diagnostics to an integrated element of care planning and longitudinal disease management.
Clinicians and laboratory leaders now confront a landscape where test choice, turnaround time, and analytic sensitivity directly influence treatment trajectories. Meanwhile, researchers leverage richer genomic datasets to refine biomarker definitions and to explore resistance mechanisms. This introduction distills those converging forces, clarifies the clinical rationale for genomic interrogation in lung oncology, and sets the stage for deeper discussion of technological, regulatory, and market dynamics that will determine adoption and implementation strategies across institutional settings.
An incisive synthesis of transformative shifts reshaping lung cancer genomics across technological advances, regulatory change, and clinician-driven adoption trends
The lung cancer genomic testing landscape is undergoing transformative shifts driven by a convergence of technological innovation, regulatory adaptation, and changing clinical workflows. Next-generation sequencing platforms have matured in throughput and analytic robustness, prompting laboratories to reconsider single-gene approaches in favor of multiplexed panels that can detect broader mutational spectra. Concurrently, improvements in sample processing and bioinformatics have reduced false negatives and enabled detection of low-frequency variants, which elevates confidence in clinical decision-making. Regulatory agencies have also moved toward clearer validation pathways and guidance for companion diagnostics, which has reduced ambiguity for developers and accelerated clinical deployment.
Adoption drivers extend beyond raw technical performance; clinician familiarity, payer engagement, and the emergence of liquid biopsy as a minimally invasive alternative have reshaped ordering behavior. At the same time, consolidation among diagnostic providers and strategic partnerships between academic centers and industry stakeholders are influencing pathways to scale. These systemic changes create both opportunities and operational challenges, requiring care providers and developers to align technology selection, quality management, and clinical utility evidence in order to optimize patient outcomes and institutional value realization.
A focused review of cumulative implications from United States tariff actions in 2025 on lung cancer genomic testing supply chains, costs and sourcing
Tariff measures introduced by the United States in 2025 have the potential to influence components of the lung cancer genomic testing ecosystem, particularly where key instruments, reagents, or specialty consumables rely on cross-border supply chains. When import duties affect sequencing platforms or essential reagents, laboratories and manufacturers may encounter higher landed costs and tighter procurement timelines, prompting reassessment of sourcing strategies. In response, some organizations may accelerate qualification of alternative suppliers, increase inventory buffers, or pursue regional procurement partnerships to mitigate exposure.
Beyond direct cost implications, tariff actions can catalyze strategic shifts in manufacturing and distribution. Domestic manufacturing investments or regionalization of supply chains may gain traction as stakeholders seek resilience against trade policy volatility. At the same time, clinical programs and diagnostic labs may prioritize assays and workflows that reduce dependency on high-cost imported consumables. Overall, while tariffs introduce complexity, they also reinforce the importance of supply chain transparency, scenario planning, and flexible contracting to sustain uninterrupted diagnostic capacity and protect patient care pathways.
A granular segmentation insight outlining technology platforms, test modalities, clinical applications, and end-user settings to guide adoption and research
A nuanced view of segment-level dynamics illuminates where clinical value and operational trade-offs converge across technology, test type, application, and end-user domains. From a technology perspective, traditional platforms such as Fluorescence In Situ Hybridization and Microarray retain roles where specific structural or copy-number assessments are required, and Real Time Polymerase Chain Reaction continues to offer rapid targeted interrogation. Sanger Sequencing remains relevant for orthogonal confirmation. At the same time, Next Generation Sequencing has become central to comprehensive genomic profiling, with targeted sequencing prioritized for focused, clinically actionable panels while whole exome and whole genome sequencing support broader discovery and complex variant interpretation in research and advanced clinical cases.
Test modality distinctions shape pre-analytical and logistical decisions. Liquid biopsy workflows that analyze circulating tumor cells and circulating tumor DNA enable minimally invasive serial monitoring and have gained traction where tissue access is limited, whereas tissue biopsy approaches such as fine needle aspiration and tissue section analyses still provide critical histopathologic and microenvironment context. Clinical applications vary by evidence need: companion diagnostics directly inform therapy selection, predictive testing anticipates therapeutic response, prognostic testing informs outcome expectations, and treatment monitoring tracks disease dynamics over time. End users span academic and research institutes focusing on discovery and validation, hospitals and diagnostic laboratories managing routine clinical testing and patient care integration, and pharmaceutical and biotechnology companies driving assay development and companion diagnostic strategies. These segmentation perspectives collectively guide investment, validation priorities, and adoption pathways for stakeholders aiming to align technology capabilities with clinical utility and operational capacity.
Regional insights revealing key drivers and barriers across the Americas, Europe Middle East & Africa, and Asia-Pacific with implications for clinical adoption
Regional dynamics exert measurable influence on how lung cancer genomic testing is deployed, reimbursed, and integrated into clinical practice. In the Americas, mature clinical infrastructures and high uptake of targeted therapies have driven demand for comprehensive genomic profiling and rapid-turnaround diagnostics. This environment encourages innovation in laboratory workflows and commercial partnerships, while regulatory clarity and payer engagement shape value demonstrations needed for broader access. In contrast, the Europe, Middle East & Africa region presents heterogeneous regulatory regimes and infrastructure maturity, requiring adaptable implementation frameworks and localized evidence generation to support clinical adoption across diverse healthcare systems.
Asia-Pacific features a mix of advanced genomic capabilities in select centers and rapidly expanding molecular diagnostics capacity in emerging markets. Regional manufacturers and public health initiatives play influential roles in scaling access, and localized validation efforts often accelerate clinical acceptance. Across regions, stakeholders must account for differences in reimbursement models, laboratory accreditation standards, and clinician education needs. Consequently, successful regional strategies blend global best practices with tailored operational models that reflect local regulatory expectations, procurement mechanisms, and patient care pathways.
An authoritative analysis of industry players highlighting strategic partnerships, technology portfolios, and competitive positioning shaping the genomic ecosystem
Industry participants are shaping the genomic testing environment through differentiated strategies that emphasize platform specialization, portfolio breadth, and collaborative development. Some organizations prioritize deep investments in bioinformatics and end-to-end laboratory automation to deliver faster, higher-fidelity results at scale, while others focus on niche assays or proprietary biomarkers to support therapeutic pipelines. Partnerships between diagnostic providers and pharmaceutical organizations have emerged as an important route to validate companion diagnostics and to streamline co-development pathways that align assay performance with therapeutic labeling and trial enrollment criteria.
Competitive positioning is also influenced by service models and quality assurance capabilities. Reference laboratories offering centralized testing can leverage scale and standardized processes, whereas academic and hospital laboratories often emphasize integrated clinical interpretation and bespoke testing tailored to complex cases. Across the ecosystem, leaders differentiate by investing in clinical evidence generation, expanding interoperability with electronic health records, and demonstrating workflow efficiencies that reduce barriers to clinician adoption. Strategic collaborations, targeted acquisitions, and co-development agreements remain central tools through which companies seek to enhance technical capability and clinical reach within the genomic ecosystem.
Practical and prioritized recommendations for industry leaders to accelerate clinical integration, optimize operational resilience, and align commercial strategies
Leaders across industry, clinical laboratories, and research institutions can advance adoption and impact by focusing on pragmatic, prioritized actions that address immediate operational constraints while positioning organizations for future technical evolution. First, aligning assay selection with clinical pathways and the institution’s therapeutic landscape reduces unnecessary complexity and accelerates clinician uptake. Second, investing in robust pre-analytical workflows and quality management mitigates variability and preserves diagnostic accuracy during scale-up. These operational investments often yield faster, more consistent results that improve clinician confidence and patient outcomes.
In parallel, stakeholders should accelerate evidence generation for clinical utility by embedding genomic testing into care pathways and prospective data collection, thereby strengthening reimbursement narratives. Strategic supplier diversification and validation of alternative reagents or platforms enhance supply chain resilience. Finally, fostering multidisciplinary education for clinicians, pathologists, and laboratory staff improves test ordering appropriateness and interpretation. Executed in combination, these recommendations support sustainable adoption, reduce time-to-result, and create clear value propositions for payers, clinicians, and patients.
A transparent research methodology describing data sources, analytical frameworks, expert validation, and the triangulation approach used to ensure rigor
The research underpinning this report combines primary expert interviews, secondary literature review, and systematic technology assessment to produce a transparent and reproducible analytic framework. Primary inputs included discussions with laboratory directors, clinical oncologists, industry strategists, and regulatory experts to surface operational realities and adoption drivers. Secondary sources provided background on technology capabilities, assay validation approaches, and regulatory guidance, and were selected to complement and corroborate primary insights rather than to serve as sole evidence.
Analytic rigor was achieved through triangulation across data sources, cross-validation of technology performance claims, and structured evaluation of clinical utility arguments. Where differences in perspective emerged, iterative expert review sessions clarified interpretation and aligned findings with practical workflows. The methodology emphasizes traceability and clarity in how conclusions were derived, enabling readers to assess evidence strength and to apply insights appropriately within their own institutional contexts.
A concise conclusion summarizing implications of genomic testing advances, policy shifts, and priorities for clinical, research and commercial stakeholders
The cumulative assessment reinforces that lung cancer genomic testing occupies a central role in contemporary oncology, with technology maturity and clinical demand accelerating integration into diagnostic pathways. Advances in sequencing and minimally invasive testing expand opportunities for earlier detection of actionable alterations and for monitoring disease evolution, but successful implementation requires coordinated attention to assay selection, quality assurance, clinician education, and supply chain robustness. Policy dynamics and regional differences further shape what operational models succeed in specific healthcare contexts.
Looking forward, stakeholders that combine thoughtful technology choices with rigorous evidence generation and resilient operational practices will be best positioned to translate genomic insights into improved patient outcomes. Collaboration across clinical, laboratory, and commercial domains will remain essential to align incentives and to ensure that diagnostic innovation meaningfully supports treatment personalization and health system value creation.
Note: PDF & Excel + Online Access - 1 Year
Table of Contents
191 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency
- 1.5. Language
- 1.6. Stakeholders
- 2. Research Methodology
- 3. Executive Summary
- 4. Market Overview
- 5. Market Insights
- 5.1. Emergence of liquid biopsy assays for early detection of actionable lung cancer mutations using blood samples
- 5.2. Integration of AI-driven bioinformatics platforms for rapid analysis of complex genomic profiles in NSCLC patients
- 5.3. Adoption of comprehensive next generation sequencing panels to identify rare driver mutations and resistance mechanisms
- 5.4. Growth of companion diagnostic approvals for targeted therapies in ALK, ROS1, EGFR mutated non small cell lung cancer
- 5.5. Expansion of decentralized genomic testing services to improve accessibility in remote and underserved patient populations
- 5.6. Implementation of reimbursement frameworks and value-based pricing models for advanced lung cancer genomic tests
- 6. Cumulative Impact of United States Tariffs 2025
- 7. Cumulative Impact of Artificial Intelligence 2025
- 8. Lung Cancer Genomic Testing Market, by Technology
- 8.1. Fluorescence In Situ Hybridization
- 8.2. Microarray
- 8.3. Next Generation Sequencing
- 8.3.1. Targeted Sequencing
- 8.3.2. Whole Exome Sequencing
- 8.3.3. Whole Genome Sequencing
- 8.4. Real Time Polymerase Chain Reaction
- 8.5. Sanger Sequencing
- 9. Lung Cancer Genomic Testing Market, by Test Type
- 9.1. Liquid Biopsy
- 9.1.1. Circulating Tumor Cells
- 9.1.2. Circulating Tumor Dna
- 9.2. Tissue Biopsy
- 9.2.1. Fine Needle Aspiration
- 9.2.2. Tissue Section
- 10. Lung Cancer Genomic Testing Market, by Application
- 10.1. Companion Diagnostics
- 10.2. Predictive Testing
- 10.3. Prognostic Testing
- 10.4. Treatment Monitoring
- 11. Lung Cancer Genomic Testing Market, by End User
- 11.1. Academic And Research Institutes
- 11.2. Hospitals And Diagnostic Laboratories
- 11.3. Pharmaceutical And Biotechnology Companies
- 12. Lung Cancer Genomic Testing Market, by Region
- 12.1. Americas
- 12.1.1. North America
- 12.1.2. Latin America
- 12.2. Europe, Middle East & Africa
- 12.2.1. Europe
- 12.2.2. Middle East
- 12.2.3. Africa
- 12.3. Asia-Pacific
- 13. Lung Cancer Genomic Testing Market, by Group
- 13.1. ASEAN
- 13.2. GCC
- 13.3. European Union
- 13.4. BRICS
- 13.5. G7
- 13.6. NATO
- 14. Lung Cancer Genomic Testing Market, by Country
- 14.1. United States
- 14.2. Canada
- 14.3. Mexico
- 14.4. Brazil
- 14.5. United Kingdom
- 14.6. Germany
- 14.7. France
- 14.8. Russia
- 14.9. Italy
- 14.10. Spain
- 14.11. China
- 14.12. India
- 14.13. Japan
- 14.14. Australia
- 14.15. South Korea
- 15. Competitive Landscape
- 15.1. Market Share Analysis, 2024
- 15.2. FPNV Positioning Matrix, 2024
- 15.3. Competitive Analysis
- 15.3.1. Abbott Laboratories
- 15.3.2. Admera Health
- 15.3.3. Agilent Technologies, Inc.
- 15.3.4. BGI
- 15.3.5. CD Genomics
- 15.3.6. CeGaT GmbH
- 15.3.7. Centogene N.V.
- 15.3.8. F. Hoffmann-La Roche AG
- 15.3.9. Illumina, Inc.
- 15.3.10. Laboratory Corporation of America Holdings
- 15.3.11. NeoGenomics Laboratories
- 15.3.12. OncoDNA
- 15.3.13. OPKO Health, Inc.
- 15.3.14. QIAGEN N.V.
- 15.3.15. Quest Diagnostics Incorporated
- 15.3.16. Thermo Fisher Scientific, Inc.
- 15.3.17. Veracyte, Inc.
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
